Matthews International Capital Management’s ResMed RMD Stock Holding History

Matthews International Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-728,400	Closed	-$61.7M	–	41
2017 Q4	$61.7M	Sell	728,400 -69,000	-9%	-$5.7M	2.92%	11
2017 Q3	$61.4M	Sell	797,400 -37,200	-4%	-$2.85M	2.54%	13
2017 Q2	$65M	Sell	834,600 -51,100	-6%	-$3.66M	2.95%	11
2017 Q1	$63.7M	Sell	885,700 -211,700	-19%	-$14.6M	3.25%	10
2016 Q4	$68.1M	Sell	1,097,400 -62,100	-5%	-$3.8M	3.51%	11
2016 Q3	$75.1M	Sell	1,159,500 -64,800	-5%	-$4.31M	3.09%	12
2016 Q2	$77.4M	Hold	1,224,300	–	–	3.38%	10
2016 Q1	$70.8M	Buy	1,224,300 +1,217,800	+18,735%	+$68.9M	3.14%	11
2015 Q4	$349K	Hold	6,500	–	–	0.02%	35
2015 Q3	$331K	Buy	+6,500	New	+$350K	0.01%	35

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Matthews International Capital Management's RMD Position: Q1 2018 in Review

Matthews International Capital Management sold out of ResMed (RMD) in Q1 2018, closing a stake of 728,400 shares — an estimated $61.7M sold.

Matthews International Capital Management first reported a position in RMD in Q3 2015 and held it in 10 quarters. The position peaked at $77.4M in Q2 2016. 445 funds tracked by Wall St. Rank hold RMD as of Q1 2018.

Matthews International Capital Management reported no remaining ResMed position as of Q1 2018 after selling out during the quarter.
Matthews International Capital Management sold 728,400 ResMed shares in Q1 2018, an estimated $61.7M.
Matthews International Capital Management first reported a position in ResMed in Q3 2015 and held it in 10 quarters.
Matthews International Capital Management's ResMed position peaked at $77.4M in Q2 2016.
445 funds tracked by Wall St. Rank held ResMed as of Q1 2018.

Based on Matthews International Capital Management's 13F filing for Q1 2018, filed 10 May 2018.